Invivyd (NASDAQ:IVVD) Announces Earnings Results, Beats Expectations By $0.01 EPS

Invivyd (NASDAQ:IVVD) released its earnings results on Thursday. The company reported ($0.14) EPS for the quarter, topping analysts’ consensus estimates of ($0.15) by $0.01, FiscalAI reports. The company had revenue of $14.29 million during the quarter, compared to analysts’ expectations of $14.40 million. Invivyd had a negative net margin of 138.90% and a negative return on equity of 53.48%.

Invivyd Price Performance

NASDAQ:IVVD traded down $0.05 during midday trading on Thursday, hitting $0.69. The company’s stock had a trading volume of 1,975,083 shares, compared to its average volume of 3,107,846. Invivyd has a fifty-two week low of $0.48 and a fifty-two week high of $3.07. The firm has a market cap of $202.01 million, a P/E ratio of -2.21 and a beta of 0.71. The firm’s 50 day moving average is $0.79 and its 200-day moving average is $1.26.

Analyst Ratings Changes

IVVD has been the subject of a number of research analyst reports. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Invivyd in a report on Friday, July 24th. BTIG Research reissued a “buy” rating on shares of Invivyd in a report on Tuesday, July 7th. Wall Street Zen downgraded Invivyd from a “hold” rating to a “strong sell” rating in a research report on Saturday, May 16th. Finally, HC Wainwright restated a “buy” rating and issued a $10.00 target price on shares of Invivyd in a research note on Monday, June 15th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, Invivyd presently has a consensus rating of “Hold” and a consensus target price of $8.00.

Institutional Trading of Invivyd

Several large investors have recently made changes to their positions in IVVD. Janus Henderson Group PLC increased its stake in shares of Invivyd by 28.2% in the fourth quarter. Janus Henderson Group PLC now owns 32,543,142 shares of the company’s stock worth $80,870,000 after acquiring an additional 7,160,065 shares during the period. RA Capital Management L.P. acquired a new position in Invivyd during the third quarter valued at $18,831,000. ADAR1 Capital Management LLC purchased a new stake in Invivyd in the third quarter valued at $8,108,000. Vanguard Group Inc. boosted its holdings in Invivyd by 46.7% in the third quarter. Vanguard Group Inc. now owns 5,762,894 shares of the company’s stock valued at $6,339,000 after purchasing an additional 1,834,970 shares during the last quarter. Finally, State Street Corp boosted its holdings in Invivyd by 1,636.7% in the fourth quarter. State Street Corp now owns 5,637,593 shares of the company’s stock valued at $13,925,000 after purchasing an additional 5,312,986 shares during the last quarter. 70.36% of the stock is owned by hedge funds and other institutional investors.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.